Find therapies in clinical trials near you – page 4

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Study on Efruxifermin for Patients with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Study on Efruxifermin for Patients with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)